TRAF1/C5 locus is associated with response to anti-TNF in rheumatoid arthritis
© Canhão et al; licensee BioMed Central Ltd. 2012
Published: 28 November 2012
Some of the rheumatoid arthritis (RA) risk allele variants were related to tumor necrosis factor (TNF) signaling pathways which raised the hypothesis that they might influence the response to anti-TNF drugs.
The primary aim of our work was to investigate potential association between the HLA-DRB1 and RA risk alleles specifically selected for their relevance on RA biologic pathways with the response to anti-TNF treatment in a Southern European population using a nationwide register.
We evaluated 383 RA patients for associations between anti-TNF treatment response assessed by an absolute change in DAS28 at six months as the primary outcome, and seven single nucleotide polymorphisms (SNP). We also studied the same association taking the proportion of EULAR good responders and non responders at six months as the outcome. Univariate and multivariate linear and logistic regression analyses were performed, adjusting for clinical variables that influenced treatment response.
The minor allele (G), which is the risk allele for RA susceptibility, rs3761847 SNP in the TRAF1/C5 region was associated with a poor anti-TNF treatment response either in linear (coefficient -0.24; 95% confidence interval (CI) -0.43, -0.06; p-value 0.009) and in logistic univariate (odds ratio (OR) 0.61; CI 0.41, 0.92; p-value 0.018) and multivariate regression analyses.
Associations between HLA-DRB1 or the other allele variants with the response to anti-TNF treatment were not observed.
The rs3761847 TRAF1/C5 risk RA locus influenced the anti-TNF treatment response in the Southern European population assessed in this study. Additional studies in other populations are necessary to confirm the relevance of this finding.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.